Frequency of Inhibitors among known Hemophilia A Patients.

ABSTRACT Introduction: Inhibitors are IgG alloantibodies which are directed against exogenous clotting factor VIII that neutralize the function of infused clotting factor concentrate used for the treatment. The prevalence of inhibitors in Hemophilia A is around 30% worldwide. Inhibitors occurs as a result of natural immune process of the body as factor concentrates used for treatment are foreign to the body and patient’s own body either produces no factor or produces structurally abnormal protein. Objectives: To determine the frequency of inhibitors among known hemophilia A patients. Methods: Cross-sectional survey done including 100 male patients of hemophilia A and on treatment for more than 1 year, from 2 to 60 years of age, were included. All the patients were undergone aPTT based screening for inhibitor, both immediately and two hours after mixing the patients plasma with the normal plasma. Results: Age range in this study was from 2 to 60 years with mean age of 37.21 ± 14.73 years. Frequency of inhibitors among known hemophilia A patients was seen in 18 (18.0%) of cases. Conclusion: This study concluded that frequency of inhibitors among known hemophilia A patients is quite high. Keywords: Hemophilia A, inhibitors, severity.